Business Context and Reporting Period
Company: DAXOR CORP
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2011
Business Overview: Daxor is a medical device manufacturer focused on the BVA-100 Blood Volume Analyzer and related Volumex kits, alongside cryobanking services. The company maintains a significant investment portfolio (primarily utility stocks) to generate income and offset operating losses.
Key Financial Metrics (Six Months Ended June 30, 2011)
| Metric | Value |
|---|---|
| Total Revenues | $735,608 |
| Net Loss | $(1,510,782) |
| Loss Per Share (Basic & Diluted) | $(0.36) |
| Cash and Cash Equivalents | $111,769 |
| Net Cash Used in Operating Activities | $(4,905,503) |
| Net Cash Provided by Financing Activities | $5,017,632 |
| Total Assets | $96,237,008 |
| Total Liabilities | $50,656,255 |
| Stockholders' Equity | $45,580,753 |
| Margin Loans Payable | $6,282,202 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 3.8% to $735,608 from $764,604 in the prior year period, driven primarily by a reduction in cryobanking services revenue.
- Operating Loss Expansion: Operating loss increased to $(3,519,734) from $(2,847,226) in the prior year. This was largely due to a $1.01 million increase in legal expenses related to an SEC administrative proceeding.
- Net Loss vs. Net Income: The company reported a net loss of $(1,510,782) compared to a net income of $95,937 in the prior year period.
- Investment Activity: While realized gains on securities decreased, the company recorded a significant mark-to-market loss on short sales of options of $(6,155,563), partially offset by realized gains of $6,024,047.
- Liquidity: Cash and cash equivalents increased from $57,741 to $111,769, supported by net proceeds from margin loans ($5.69 million net inflow).
Guidance, Outlook, Risks, and Contingencies
- SEC Administrative Proceeding: The SEC is claiming Daxor is an unregistered investment company rather than an operating company. An initial decision was extended to September 6, 2011. If found to be an investment company, Daxor may need to register as a Regulated Investment Company (RIC), requiring the distribution of 90% of taxable income to shareholders.
- Key Person Risk: The company is heavily dependent on Dr. Joseph Feldschuh (CEO), who makes all investment decisions and is the primary scientist. The filing notes that if he were unable to continue, the company would likely cease option trading, potentially resulting in insufficient income to cover operating losses.
- Investment Strategy: The portfolio is primarily invested in electric utilities. Management maintains short positions (up to 15% of portfolio value) and sells put/call options to generate income. Significant unrealized losses exist in Bank of America, Citigroup, and USEC holdings, though management does not believe an impairment charge is necessary.
- Reimbursement Risk: CMS policy changes have eliminated separate Medicare reimbursement for Daxor's Volumex radiopharmaceuticals for outpatient services, requiring hospitals to absorb the cost. The impact of this on future sales remains a risk.
Investor Verification Checklist
- SEC Proceeding Outcome: Verify the final ruling on the SEC administrative proceeding regarding Daxor's status as an investment company and the potential requirement to distribute 90% of income.
- Investment Portfolio Valuation: Review the specific unrealized losses in Bank of America, Citigroup, and USEC and assess the risk of future impairment charges if market conditions deteriorate.
- Succession Planning: Evaluate the contingency plans for investment management and scientific leadership in the event of Dr. Feldschuh's unavailability.
- Operating Cash Flow: Monitor the company's ability to fund operations without relying on margin loans, given the continued operating losses and cash burn.
- Customer Concentration: Note that four hospitals accounted for approximately 60% of Blood Volume Kit sales; verify the stability of these key accounts.